MIRJAM-HELIN-COMPETITION
8.2.2024 12:01:37 CET | Business Wire | Press release
56 talented young singers were selected to compete for the first prize of 50,000 euro in the Mirjam Helin competition in Helsinki, Finland next June.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208343535/en/
One of the 2019 winners Johanna Wallroth singing with the Finnish Radio Symphony Orchestra and conductor Hannu Lintu. Photo by Heikki Tuuli.
Based on video pre-screening, the Mirjam Helin competition selected 56 out of 485 applicants for the competition in Helsinki next June. Altogether 61 nationalities were represented among the applicants.
Soile Isokoski, opera singer and chair of the Mirjam Helin competition jury is delighted to see that the competition attracted such highly promising and talented singers.
“Naturally, the first criterion is the applicant’s voice, but this is just the starting point. We look for singers who perform the music as it is intended but who also go beyond the notes, bring the song to life and master all the different genres. Verdi and Mozart cannot be sung in the same way,” Isokoski says.
South Korea has the highest number of applicants accepted to the competition, thirteen in total. Four of the competitors are from Finland. The competitors represent 25 nationalities, with participants from countries such as Armenia, Germany, Costa Rica, China, the United States, Croatia and Australia. For a full list of competitors, see mirjamhelin.fi.
The preliminary competition with piano accompaniment will take place from 3 to 6 June 2024. The jury selects 16–20 singers for the semifinals, and six will be eligible for the orchestral finals on 12 June. In the orchestral finals, the singers will perform with the Helsinki Philharmonic, led by Sir Mark Elder.
The jury members are soprano Dawn Upshaw, mezzosoprano Randi Stene, baritone Bo Skovhus, pianist Keval Shah and chair, soprano Soile Isokoski.
The Mirjam Helin competition is celebrating its 40th anniversary this year. The winner will be awarded the first prize of 50,000 euro; the second prize is 40,000 euro, the third prize 30,000 euro, and the other three finalists will receive 10,000 euro each. The finalists will also have opportunities to perform at Finnish music festivals and with Finnish orchestras.
The Finnish Cultural Foundation has been organizing the international Mirjam Helin competition since 1984. The competition is founded on Mirjam ja Hans Helin’s large donation. Professor Mirjam Helin’s (1911–2006) aim was to establish an international singing competition in Finland and to make it the most prestigious competition globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208343535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
